The annual meeting of the American College of Gastroenterology was held from Oct. 24 to 29 in Phoenix, attracting participants from around the world, including gastroenterology and digestive disease ...

An Institute for Clinical and Economic Review report concluded that the GLP-1 drugs tirzepatide and semaglutide (Ozempic, ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited ...

People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to experience cardiovascular death, heart attack or stroke ...

Microdosing GLP-1 weight loss drugs like semaglutide is trendy, with supporters touting benefits such as lower costs and potentially fewer side effects. But some doctors are skeptical, calling it ...

The three GLP-1 receptor agonist (RA) drugs liraglutide (Victoza), semaglutide (Ozempic), and dulaglutide (Trulicity) provided similar cardiovascular and kidney benefits in people with type 2 diabetes ...

In the trial, 136 adults with overweight or obesity were randomly assigned to receive weekly injections of nimacimab, semaglutide, both drugs together, or placebo. Participants who received nimacimab ...

Semaglutide 7.2 mg, compared with semaglutide 2.4 mg and placebo, was associated with superior efficacy outcomes and comparable safety among patients with obesity. Use of semaglutide 7.2 mg vs 2.4 mg ...

Semaglutide or tirzepatide should be first-line drugs for obesity and most of its related complications, new guidance from the European Association for the Study of Obesity recommended. The authors of ...

New findings presented by Jörn Schattenberg at UEG Week 2025 in Berlin, Germany, demonstrate that semaglutide 2.4 mg provides significant improvements in metabolic dysfunction-associated ...